#METABOLOMICS WORKBENCH hormel101_20160701_074354 DATATRACK_ID:659 STUDY_ID:ST000422 ANALYSIS_ID:AN000667 PROJECT_ID:PR000330 VERSION 1 CREATED_ON July 18, 2016, 11:39 am #PROJECT PR:PROJECT_TITLE Impact of Long-Term Poor and Good Glycemic Control on Metabolomics Alterations PR:PROJECT_TITLE in Type 1 Diabetic People. PR:PROJECT_TYPE Untargeted LC-MS Metabolomics PR:PROJECT_SUMMARY The objective of the study was to determine whether T1D with good glycemic PR:PROJECT_SUMMARY control have persistent abnormalities of metabolites and pathways that exist in PR:PROJECT_SUMMARY T1D with poor glycemic control. PR:INSTITUTE Mayo Clinic PR:DEPARTMENT Endocrinology PR:LABORATORY Mayo Clinic Metabolomics Resource Core PR:LAST_NAME Nair PR:FIRST_NAME Sreekumaran PR:ADDRESS 200 First Street SW, Rochester, MN 55905 PR:EMAIL Nair.K@mayo.edu PR:PHONE 507-285-2415 #STUDY ST:STUDY_TITLE Type 1 Diabetes good glycemic control and controls samples ST:STUDY_TYPE Plasma metabolites in T1 diabetes ST:STUDY_SUMMARY The objective of the study was to determine whether T1D with good glycemic ST:STUDY_SUMMARY control have persistent abnormalities of metabolites and pathways that exist in ST:STUDY_SUMMARY T1D with poor glycemic control. ST:INSTITUTE Mayo Clinic ST:DEPARTMENT Endocrinology ST:LABORATORY Mayo Clinic Metabolomics Resource Core ST:LAST_NAME Nair ST:FIRST_NAME Sreekumaran ST:ADDRESS 200 First Street SW, Rochester, MN 55905 ST:EMAIL Nair.K@mayo.edu ST:PHONE 507-285-2415 #SUBJECT SU:SUBJECT_TYPE Animal SU:SUBJECT_SPECIES Homo sapiens SU:TAXONOMY_ID 9606 #SUBJECT_SAMPLE_FACTORS: SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data SUBJECT_SAMPLE_FACTORS T1D_S01 10jan12_12-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S01 10jan12_12-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S01 10jan12_13-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S01 10jan12_13-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S02 10jan12_14-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S02 10jan12_14-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S02 10jan12_15-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S02 10jan12_15-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S03 10jan12_21-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S03 10jan12_21-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S03 10jan12_22-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S03 10jan12_22-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S04 10jan12_23-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S04 10jan12_23-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S04 10jan12_24-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S04 10jan12_24-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S05 10jan12_25-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S05 10jan12_25-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S05 10jan12_26-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S05 10jan12_26-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S06 10jan12_27-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S06 10jan12_27-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S06 10jan12_28-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S06 10jan12_28-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S07 10jan12_38-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S07 10jan12_38-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S07 10jan12_39-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S07 10jan12_39-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S08 10jan12_40-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S08 10jan12_40-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S08 10jan12_41-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S08 10jan12_41-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S09 10jan12_42-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S09 10jan12_42-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S09 10jan12_43-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S09 10jan12_43-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S10 10jan12_44-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S10 10jan12_44-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S10 10jan12_45-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S10 10jan12_45-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S11 10jan12_55-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S11 10jan12_55-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S11 10jan12_56-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S11 10jan12_56-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S12 10jan12_57-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S12 10jan12_57-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S12 10jan12_80-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S12 10jan12_80-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S13 10jan12_58-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S13 10jan12_58-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S13 10jan12_59-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S13 10jan12_59-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S14 10jan12_60-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S14 10jan12_60-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S14 10jan12_81-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S14 10jan12_81-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S15 10jan12_61-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S15 10jan12_61-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S15 10jan12_62-r001.d treatment:ND study=ms3075; rep=1; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S15 10jan12_62-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S01 08feb12_12-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S01 08feb12_12-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S01 08feb12_13-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S01 08feb12_13-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S02 08feb12_14-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S02 08feb12_14-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S02 08feb12_15-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S02 08feb12_15-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S03 08feb12_21-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S03 08feb12_21-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S03 08feb12_22-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S03 08feb12_22-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S04 08feb12_23-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S04 08feb12_23-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S04 08feb12_24-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S04 08feb12_24-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S05 08feb12_25-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S05 08feb12_25-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S05 08feb12_26-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S05 08feb12_26-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S06 08feb12_27-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S06 08feb12_27-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S06 08feb12_28-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S06 08feb12_28-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S07 08feb12_38-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S07 08feb12_38-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S07 08feb12_39-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S07 08feb12_39-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S08 08feb12_40-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S08 08feb12_40-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S08 08feb12_41-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S08 08feb12_41-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S09 08feb12_42-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S09 08feb12_42-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S09 08feb12_43-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S09 08feb12_43-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S10 08feb12_44-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S10 08feb12_44-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S10 08feb12_45-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S10 08feb12_45-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S11 08feb12_55-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S11 08feb12_55-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S11 08feb12_56-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S11 08feb12_56-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S12 08feb12_57-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S12 08feb12_57-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S12 08feb12_80-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S12 08feb12_80-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S13 08feb12_58-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S13 08feb12_58-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S13 08feb12_59-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S13 08feb12_59-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S14 08feb12_60-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S14 08feb12_60-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S14 08feb12_81-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S14 08feb12_81-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S15 08feb12_61-r001.d treatment:T1D good glycemic control study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S15 08feb12_61-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S15 08feb12_62-r001.d treatment:ND study=ms3075; rep=1; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS ND_S15 08feb12_62-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=hilic SUBJECT_SAMPLE_FACTORS T1D_S01 15feb12_12-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S01 15feb12_13-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S02 15feb12_14-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S02 15feb12_15-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S03 15feb12_21-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S03 15feb12_22-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S04 15feb12_23-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S04 15feb12_24-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S05 15feb12_25-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S05 15feb12_26-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S06 15feb12_27-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S06 15feb12_28-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S07 15feb12_38-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S07 15feb12_39-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S08 15feb12_40-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S08 15feb12_41-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S09 15feb12_42-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S09 15feb12_43-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S10 15feb12_44-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S10 15feb12_45-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S11 15feb12_55-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S11 15feb12_56-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S12 15feb12_57-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S12 15feb12_80-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S13 15feb12_58-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S13 15feb12_59-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S14 15feb12_60-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S14 15feb12_81-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S15 15feb12_61-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S15 15feb12_62-r002.d treatment:ND study=ms3075; rep=2; Ionization=positive; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S01 13feb12_12-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S01 13feb12_13-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S02 13feb12_14-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S02 13feb12_15-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S03 13feb12_21-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S03 13feb12_22-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S04 13feb12_23-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S04 13feb12_24-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S05 13feb12_25-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S05 13feb12_26-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S06 13feb12_27-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S06 13feb12_28-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S07 13feb12_38-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S07 13feb12_39-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S08 13feb12_40-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S08 13feb12_41-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S09 13feb12_42-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S09 13feb12_43-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S10 13feb12_44-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S10 13feb12_45-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S11 13feb12_55-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S11 13feb12_56-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S12 13feb12_57-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S12 13feb12_80-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S13 13feb12_58-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S13 13feb12_59-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S14 13feb12_60-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S14 13feb12_81-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS T1D_S15 13feb12_61-r002.d treatment:T1D good glycemic control study=ms3075; rep=2; Ionization=negative; Separation=C18 SUBJECT_SAMPLE_FACTORS ND_S15 13feb12_62-r002.d treatment:ND study=ms3075; rep=2; Ionization=negative; Separation=C18 #COLLECTION CO:COLLECTION_SUMMARY At 5:00 AM after an overnight fast, baseline blood samples were collected from CO:COLLECTION_SUMMARY study participants. Plasma samples were stored at 80°C until analysis. CO:SAMPLE_TYPE Blood. Plasma was isolated for MS analysis. #TREATMENT TR:TREATMENT_SUMMARY Participants were admitted to the Clinical Research Unit at St Mary’s Hospital TR:TREATMENT_SUMMARY (Rochester, Minnesota) the evening before the study and spent overnight in the TR:TREATMENT_SUMMARY Clinical Research Unit. The participants were given a standard meal on the TR:TREATMENT_SUMMARY evening of the admission after which they fasted overnight. Participants with TR:TREATMENT_SUMMARY T1D were treated with insulin as per their usual individual programs. At 5:00 AM TR:TREATMENT_SUMMARY after an overnight fast, baseline blood samples were collected from study TR:TREATMENT_SUMMARY participants. Plasma samples were stored at 80°C until analysis. #SAMPLEPREP SP:SAMPLEPREP_SUMMARY Plasma quality-control samples used in the study were prepared from pooled SP:SAMPLEPREP_SUMMARY plasma spiked with a selection of metabolites to mimic elevated levels of SP:SAMPLEPREP_SUMMARY metabolites during I− (insulin withdrawn) condition. Plasma was spiked with a SP:SAMPLEPREP_SUMMARY standard mixture (3:1 ratio of plasma to spiking solution) containing 100 μg/mL SP:SAMPLEPREP_SUMMARY niacin, hypoxanthine, leucine, isoleucine, phenylalanine, tryptophan, citric SP:SAMPLEPREP_SUMMARY acid, glucose, hippuric acid, and taurocholic acid dissolved in 1:1 SP:SAMPLEPREP_SUMMARY acetonitrile/water. All plasma samples (200 μL) were thawed on ice at 4°C SP:SAMPLEPREP_SUMMARY followed by deproteinization with methanol (1:4 ratio of plasma to methanol) and SP:SAMPLEPREP_SUMMARY vortexed for 10 s, followed by incubation at −20°C for 2 h. The samples were SP:SAMPLEPREP_SUMMARY then centrifuged at 15,871g for 30 min at 4°C. The supernatants were SP:SAMPLEPREP_SUMMARY lyophilized (Savant, Holbrook, NY) and stored at −20°C prior to analysis. The SP:SAMPLEPREP_SUMMARY samples were reconstituted in 50% H2O/acetonitrile and passed through a Microcon SP:SAMPLEPREP_SUMMARY YM3 filter (Millipore Corporation). The supernatants were transferred to SP:SAMPLEPREP_SUMMARY analytical vials, stored in the autosampler at 4°C, and analyzed within 48 h of SP:SAMPLEPREP_SUMMARY reconstitution in buffer. #CHROMATOGRAPHY CH:CHROMATOGRAPHY_SUMMARY The liquid chromatography platform consisted of an Acquity UPLC system (Waters, CH:CHROMATOGRAPHY_SUMMARY Milford, MA). Plasma metabolite separation was achieved using both hydrophilic CH:CHROMATOGRAPHY_SUMMARY interaction chromatography (ethylene-bridged hybrid 2.1 × 150 mm, 1.7 μm; CH:CHROMATOGRAPHY_SUMMARY Waters) and reversed-phase liquid chromatography C18 (high-strength silica 2.1 CH:CHROMATOGRAPHY_SUMMARY × 150 mm, 1.8 μm; Waters). For each column, the run time was 20 min at a flow CH:CHROMATOGRAPHY_SUMMARY rate of 400 μL/min. Reverse-phase chromatography was performed using 99% CH:CHROMATOGRAPHY_SUMMARY solvent A (5 mmol/L NH4 acetate, 0.1% formic acid, and 1% acetonitrile) to 100% CH:CHROMATOGRAPHY_SUMMARY solvent B (95% acetonitrile with 0.1% formic acid). The gradient was 0 min, 0% CH:CHROMATOGRAPHY_SUMMARY B; 1 min, 0% B; 3 min, 5% B; 13.0 min, 100% B; 16 min, 100% B; 16.5 min, 0% B; CH:CHROMATOGRAPHY_SUMMARY and 20 min, 0% B. Other LC parameters were injection volume 5 μL and column CH:CHROMATOGRAPHY_SUMMARY temperature 50°C. Each sample was injected in triplicate with blank injections CH:CHROMATOGRAPHY_SUMMARY between each sample. Quality controls and standards were run at the beginning CH:CHROMATOGRAPHY_SUMMARY and end of the sequence. CH:CHROMATOGRAPHY_TYPE HILIC CH:INSTRUMENT_NAME Agilent 6220 CH:COLUMN_NAME none #ANALYSIS AN:ANALYSIS_TYPE MS #MS MS:MS_COMMENTS - MS:INSTRUMENT_NAME Agilent 6220 TOF MS:INSTRUMENT_TYPE TOF MS:MS_TYPE ESI MS:ION_MODE POSITIVE MS:CAPILLARY_TEMPERATURE 300°C MS:CAPILLARY_VOLTAGE 3.5 kV MS:FRAGMENT_VOLTAGE 150 V MS:MASS_ACCURACY <5 parts per million and ~20000 respectively MS:NEBULIZER nebulizer gas 325°C MS:OCTPOLE_VOLTAGE 250 V MS:SCAN_RANGE_MOVERZ 50-1200 MS:SCANNING_CYCLE 0.5 s MS:SKIMMER_VOLTAGE 58 V MS:MS_RESULTS_FILE ST000422_AN000667_Results.txt UNITS:intensity Has m/z:Yes Has RT:Yes #END